Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Neoplasms 1Cancer Pain 1Breakthrough Pain 1

Interventions

Fentanyl 27Analgesia 23Morphine 20Acupuncture Therapy 18Surveys and Questionnaires 16Oxycodone 16Zoledronic Acid 15Acetaminophen 14Therapeutics 13Radiotherapy 13Psychiatric Rehabilitation 13Ketamine 13Methadone 11Lidocaine 11Hydromorphone 11Bupivacaine 11nabiximols 10Ibandronic Acid 10Ropivacaine 9Early Intervention, Educational 7Analgesics, Opioid 7Saline Solution 6Music Therapy 6Cryotherapy 6Cryosurgery 6Yoga 5Water 5Tapentadol 5Pregabalin 5Methods 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pain × Ultracet × Clear all
NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡